Sun Pharmaceutical Industries Ltd Share Price
(SUNPHARMA)
₹1775.2▲1.59%
as on 12:54PM, 23 Apr 2025
🔔 Growth Alert
Sun Pharma expected to deliver 12% YoY growth in the US market, driven by its specialty portfolio, according to Centrum.
Sun Pharma Performance
Day's Low
Day's High
₹1,742.1Day's Price Range₹1,777.552 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | -2.1 % |
| 3 Month Return | -4.7 % |
| 1 Year Return | + 17.7 % |
| Market Stats | |
| Previous Close | ₹1,747.40 |
| Open | ₹1,775.30 |
| Volume | 6.72L |
| Upper Circuit | ₹1,922.10 |
| Lower Circuit | ₹1,572.70 |
| Market Cap | ₹4,19,259.79Cr |
Sun Pharma Fundamentals
P/E Ratio
36.63
PEG Ratio
3.46
Market Cap
₹4,19,259.79 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
Mutual Fund Holdings of Sun Pharma
Sun Pharma Analyst Rating
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2047.89
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of17.20%
High
₹2450
Target
₹2047.89
Low
₹1500
Sun Pharma target price ₹2047.89, a slight upside of 17.2% compared to current price of ₹1775.2. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.23%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.55%
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
10:09 AM
-Sun Pharma expected to achieve 12% YoY growth in the US market, driven by its specialty portfolio.
Key events for Sun Pharmaceutical Industries Ltd
Sun Pharma Anticipates Strong US Market Growth - 23 Apr, 2025
Sun Pharmaceutical Industries is projected to deliver a 12% year-over-year growth in the US market, primarily due to the success of its specialty portfolio.Sun Pharma Shares Rise with Buy Recommendation - 20 Apr, 2025
Sun Pharmaceutical Industries Ltd shares closed at Rs.1,757.00, up 3.77%. Emkay Global recommends a Buy with a target price of Rs.2,400, suggesting a 40% upside.Sun Pharma Faces Recall Amid Regulatory Challenges - 14 Apr, 2025
Sun Pharmaceutical Industries is recalling several medicines from the US market due to manufacturing-related problems, contributing to a challenging environment for the company amid strong competition and regulatory pressures.Sun Pharma Faces Recall Amid Stock Recovery - 13 Apr, 2025
Sun Pharmaceutical Industries has seen a recovery in its stock, regaining nearly half of its earlier losses. However, it is also recalling 13,700 bottles of Gabapentin capsules due to cross-contamination concerns, which may impact investor sentiment.Sun Pharma Gains Court Approval for Leqselvi Launch - 10 Apr, 2025
Sun Pharmaceutical Industries received a favorable ruling from the U.S. Court of Appeals, lifting the injunction on Leqselvi's launch, projected to boost sales significantly in FY26 and FY27.Sun Pharma Faces Challenges from US Tariff Announcement - 09 Apr, 2025
Sun Pharmaceutical Industries Ltd is expected to face challenges due to upcoming US tariffs on pharmaceutical imports, leading to a negative trading outlook and lower stock performance.Sun Pharma Launches New Drug Amid Market Challenges - 07 Apr, 2025
Sun Pharmaceutical Industries launched FEXUCLUE for Erosive Esophagitis, demonstrating high efficacy in trials. However, shares fell 3.47% as the Nifty Pharma index hit a 10-month low.Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025
Sun Pharma shares declined due to tariff concerns after Trump's announcement, but the company is projected to achieve significant sales growth in Q4FY25, maintaining a positive outlook from analysts.Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025
On April 3, 2025, Sun Pharmaceutical Industries saw its shares rise over 5% after the U.S. confirmed that Indian pharmaceutical exports would not face new tariffs. This decision is viewed positively by brokerages, highlighting Sun Pharma's resilience amid potential tariff disruptions.Sun Pharma Reports Strong Growth Amid Challenges - 02 Apr, 2025
Sun Pharmaceutical Industries Ltd reported a 10.4% revenue growth in FY24, driven by specialty drugs and a robust Indian market, despite potential tariff pressures on exports.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Sun Pharma Enters Merger Agreement with Checkpoint Therapeutics - 29 Mar, 2025
Sun Pharmaceutical Industries Ltd has entered into a merger agreement with Checkpoint Therapeutics, Inc. This merger aims to facilitate the launch of UNLOXCYT in the U.S. and support marketing authorization in Europe, enhancing the company's strategic position in the oncology market.Sun Pharma Faces Challenges Amid Market Decline - 27 Mar, 2025
Sun Pharmaceutical Industries Ltd is impacted by Lyndra Therapeutics ceasing operations due to funding issues and a broader decline in Indian pharma stocks amid tariff concerns.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.6% return, outperforming this stock by 43.5%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 56.9% return, outperforming this stock by 39.2%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, SUNPHARMA stock has moved down by -2.1%
Sun Pharma News
RBI's Softer LCR Norms To Boost Banking Sector Credit Growth
Emkay Global Financial Services believe that most scheduled commercial banks--HDFC Bank, ICICI Bank, Axis Bank, Yes Bank and City Union Bank – would be carrying a healthy proportion of deposits from these customers.23 Apr, 2025 10:24 AMYes Bank Share Price Soars: Is a Bigger Comeback Coming?
Yes Bank share price today: Yes Banks share price continued to build on gains as it jumped another 1% in Tuesdays intraday trade (April 22) to reach ₹19 apiece. Todays rise marked the fifth consecutive day of gain for Yes Bank share price, resulting in a cumulative gain of 11%. In the previous trading session, Yes Banks share price ended with over a 4% gain, its biggest single-day jump since mid-January, as investors cheered the banks Q4FY25 results, which beat the Street estimates. The recent rally in the share price came as a big relief for the Yes Bank shareholders, who had been witnessing a steady downturn in recent months, ending eight straight months in the red between August 2024 and March 2025, losing 37% of their value. In April, the stock reversed its bearish streak, gaining nearly 12%, which is the biggest monthly gain since July 2024, as the stock recorded a gain of 11.90%. Looking at Yes Banks Q4FY24 numbers, the bank reported a net profit of ₹738.1 crore, up 63.3% YoY from ₹451.9 crore in the same quarter of the previous fiscal year. The private sector lender has seen a significant improvement in asset quality metrics, provision coverage ratio, and fresh slippages. The GNPA improved sequentially to 1.6%, NNPA to 0.3%, and PCR to 79.7% during the March 2025 quarter. The non-performing assets (NPAs) decreased to ₹800.1 crore from ₹1,142.62 crore in the previous quarter, while gross NPAs were recorded at ₹3,935.6 crore, lower than ₹3,963.47 crore. The quarters provisions were ₹318.1 crore, down from ₹470.9 crore for the year but higher than the ₹258.7 crore in the previous quarter. Yes Bank shares technical outlook Anshul Jain, Head of Research at Lakshmishree Investment and Securities, said, Yes Bank has breached the daily lower high and swing high at ₹18.42 with a gap-up move, signalling a potential shift in momentum. Pullbacks to this level present a buying opportunity for scalpers and momentum traders. The immediate upside targets lie at ₹19.5 and ₹21. However, volumes lack bullish conviction, making this a slightly risky trade. Price action is promising, but traders should stay alert for confirmation before going heavy. Kotak flags valuation concerns Domestic brokerage firm Kotak Institutional Equities has retained its Sell call on the Yes Bank share price, with a target price of ₹17 apiece, citing the expensive valuations. The brokerage has trimmed its estimates to reflect the interest rate outlook, which would have a bearing on near-term NIM, and also expects return ratios to gradually improve over time from current levels, but it doesnt see this to be gradual. We find the risk-reward proposition to be better elsewhere. We still find valuations expensive for the return ratios that the bank is delivering today and find better alternatives in the market, said Kotak.22 Apr, 2025 12:08 PMYes Bank Aims for 1% ROA Amidst Improving Financial Metrics
Falling credit cost to help Yes Bank achieve 1% ROA in next two financial years: Prashant Kumar. Yes Bank shares rally 5% on reporting 63% YoY jump in Q4 PAT. We are quite confident that in FY26, even retail would be growing between 10% and 12%. So, with the combination of these four different segments, the bank would be in a position to achieve a loan growth of 12-15%. Despite many headwinds, the deposit costs remain between 6% and 6.10% and they continue to maintain a very healthy LCR of 125%. Operating profit continuously improving – 25% this time as well and this is on account of non-interest income (NII), and a very tight control on the cost side. Improvement in the cost to income ratio which has actually come down from almost 76% for Q4 of last financial year to 67% for the current year. Loan growth is coming from four different segments. The issue on the retail side started happening somewhere in the FY24 itself and which are not only confined to us, rather was across the banking industry. The good news is that it has stabilised and if we see Q4, the slippages have started coming down. The retail slippages have come down by 40 basis points. Deposit growth which we are seeing is the published deposit growth of almost 6.8%. On the deposit side, we have achieved 16% growth on the average, where the current account was more than 20% and savings bank was more than 32%. We have taken those steps where the cost of deposit in the current financial year would come down and in terms of RIDF deposits are also coming down from 11% to 8.7% and in next two years it would come down to less than 5%. We continue to stick to our guidance of 1% ROA for the FY27, but we are also confident that in the current financial year when we are exiting in the fourth quarter of the FY26, we would be targeting a 1% ROA and this would be mainly coming from by improvement in the margins which would be a function of the NII, non-interest income, and the control on the cost side.22 Apr, 2025 08:11 AMSun Pharma Financials
Sun Pharma Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.05% | 0.17 | |
| Mutual Funds | 12.24% | 1.02 | |
| Retail Investors | 8.92% | 0.33 | |
| Others | 6.31% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (36.63x)
April 22, 2025
Industry (53.69x)
April 22, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.37%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceutical Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,19,259.79 Cr | 53.2% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,56,931.75 Cr | 28.91% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,867.99 Cr | 33.6% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹40,076.03 Cr | -0.8% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,904.51 Cr | -4.05% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Sun Pharmaceutical Industries Ltd
What is Sun Pharmaceutical Industries Ltd price today?
Sun Pharmaceutical Industries Ltd share price today stands at ₹1775.2, Open: ₹1775.3, Previous Close: ₹1747.4, High: ₹1777.5, Low: ₹1742.1, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceutical Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceutical Industries Ltd shares
What are today's traded volumes of Sun Pharmaceutical Industries Ltd?
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 6.72L.
What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹419259.79Cr.
What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?
How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1775.2. It is down -9.44% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1775.2. It is up 28.90% from its 52 Week Low price of ₹1377.2